| Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation KM Sakamoto, KB Kim, A Kumagai, F Mercurio, CM Crews, RJ Deshaies Proceedings of the National Academy of Sciences 98 (15), 8554-8559, 2001 | 2224 | 2001 |
| PROTAC targeted protein degraders: the past is prologue M Békés, DR Langley, CM Crews Nature Reviews Drug Discovery 21 (3), 181-200, 2022 | 1820 | 2022 |
| Induced protein degradation: an emerging drug discovery paradigm AC Lai, CM Crews Nature reviews Drug discovery 16 (2), 101-114, 2017 | 1309 | 2017 |
| The Primary Structure of MEK, a Protein Kinase that Phosphorylates the ERK Gene Product CM Crews, A Alessandrini, RL Erikson Science 258 (5081), 478-480, 1992 | 1306 | 1992 |
| Catalytic in vivo protein knockdown by small-molecule PROTACs DP Bondeson, A Mares, IED Smith, E Ko, S Campos, AH Miah, ... Nature chemical biology 11 (8), 611-617, 2015 | 1244 | 2015 |
| Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity L Meng, R Mohan, BHB Kwok, M Elofsson, NY Sin, CM Crews Proceedings of the National Academy of Sciences 96 (18), 10403-10408, 1999 | 1242 | 1999 |
| Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4 J Lu, Y Qian, M Altieri, H Dong, J Wang, K Raina, J Hines, JD Winkler, ... Chemistry & biology 22 (6), 755-763, 2015 | 1190 | 2015 |
| The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2 N Sin, L Meng, MQW Wang, JJ Wen, WG Bornmann, CM Crews Proceedings of the National Academy of Sciences 94 (12), 6099-6103, 1997 | 855 | 1997 |
| PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer K Raina, J Lu, Y Qian, M Altieri, D Gordon, AMK Rossi, J Wang, X Chen, ... Proceedings of the National Academy of Sciences 113 (26), 7124-7129, 2016 | 851 | 2016 |
| Lessons in PROTAC design from selective degradation with a promiscuous warhead DP Bondeson, BE Smith, GM Burslem, AD Buhimschi, J Hines, ... Cell chemical biology 25 (1), 78-87. e5, 2018 | 803 | 2018 |
| Proteolysis-targeting chimeras as therapeutics and tools for biological discovery GM Burslem, CM Crews Cell 181 (1), 102-114, 2020 | 790 | 2020 |
| Molecular understanding and modern application of traditional medicines: triumphs and trials TW Corson, CM Crews Cell 130 (5), 769-774, 2007 | 739 | 2007 |
| Targeted protein degradation: expanding the toolbox M Schapira, MF Calabrese, AN Bullock, CM Crews Nature reviews Drug discovery 18 (12), 949-963, 2019 | 733 | 2019 |
| Modular PROTAC design for the degradation of oncogenic BCR‐ABL AC Lai, M Toure, D Hellerschmied, J Salami, S Jaime‐Figueroa, E Ko, ... Angewandte Chemie International Edition 55 (2), 807-810, 2016 | 708 | 2016 |
| The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IκB kinase BHB Kwok, B Koh, MKI Ndubuisi, M Elofsson, CM Crews Chemistry & biology 8 (8), 759-766, 2001 | 692 | 2001 |
| Small‐molecule PROTACS: new approaches to protein degradation M Toure, CM Crews Angewandte Chemie International Edition 55 (6), 1966-1973, 2016 | 682 | 2016 |
| PROteolysis TArgeting Chimeras (PROTACs)—past, present and future M Pettersson, CM Crews Drug Discovery Today: Technologies 31, 15-27, 2019 | 681 | 2019 |
| The ubiquitin‐proteasome pathway and proteasome inhibitors J Myung, KB Kim, CM Crews Medicinal research reviews 21 (4), 245-273, 2001 | 643 | 2001 |
| Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics AR Schneekloth, M Pucheault, HS Tae, CM Crews Bioorganic & medicinal chemistry letters 18 (22), 5904-5908, 2008 | 634 | 2008 |
| The advantages of targeted protein degradation over inhibition: an RTK case study GM Burslem, BE Smith, AC Lai, S Jaime-Figueroa, DC McQuaid, ... Cell chemical biology 25 (1), 67-77. e3, 2018 | 624 | 2018 |